ImmunoPrecise Antibodies Ltd. (HYFT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
MindWalk Holdings Corp. (HYFT) Reports Q1 Loss, Misses Revenue Estimates
MindWalk Holdings Corp. (HYFT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.07 per share a year ago.
MindWalk Q1 Earnings Call Highlights
MindWalk NASDAQ: HYFT reported first-quarter fiscal 2027 revenue of CAD 3.8 million, up 21% from CAD 3.2 million a year earlier, as the company continued investing in commercialization of its ReefIQ biological-data platform and expanded its drug discovery partnership model.
MindWalk Holdings Corp. (HYFT) Q4 2026 Earnings Call Transcript
MindWalk Holdings Corp. (HYFT) Q4 2026 Earnings Call Transcript
MindWalk Holdings Corp. (HYFT) Reports Q4 Loss, Misses Revenue Estimates
MindWalk Holdings Corp. (HYFT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.04 per share a year ago.
MindWalk Holdings Corp. (HYFT) Q3 2026 Earnings Call Transcript
MindWalk Holdings Corp. (HYFT) Q3 2026 Earnings Call Transcript
MindWalk Holdings Corp. (HYFT) Reports Q3 Loss, Lags Revenue Estimates
MindWalk Holdings Corp. (HYFT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.06 per share a year ago.
MindWalk Holdings Corp. (HYFT) Q2 2026 Earnings Call Transcript
MindWalk Holdings Corp. (HYFT) Q2 2026 Earnings Call Transcript
MindWalk Holdings Corp. (HYFT) Reports Q2 Loss, Lags Revenue Estimates
MindWalk Holdings Corp. (HYFT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.07 per share a year ago.
